Think I agree with you there gbsm.
The price has been flat for a while now with lots of comments of bots, instos etc trying to keep it down. The course of sales with numerous small sales that can't even cover retail brokerage costs suggest its all insto sell downs to have captial to re-invest at CR time.
The CEO has often said that his prefered method to raise for the trial was the option that provided best return for shareholders so it suggests they will raise and go at EMA DMD alone.
The new info from Vinceanna reference 3 month tox study is pivitol for the FDA trial moving forward. Great find there.
There's something telling me that moving forward with the EMA is somewhat dependant on hearing back from FDA, I'm not sure why, maybe the sharing of data or something, but I recall making a note after the last presentation that rang a few bells for me. Maybe I'm trying to join dots that aren't there ??
Anyway, while the price keeps dropping, the scene for a sophisticated CR gets stronger for me.
Good luck all.
ANP Price at posting:
19.5¢ Sentiment: Buy Disclosure: Held
